Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H32O2 |
Molecular Weight | 328.4883 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 6 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
InChI
InChIKey=MBMBGCFOFBJSGT-KUBAVDMBSA-N
InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28314621Curator's Comment: description was created based on several sources, including
https://www.hsph.harvard.edu/nutritionsource/omega-3-fats/ |
https://www.ncbi.nlm.nih.gov/pubmed/24352849 |
https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm134064.htm
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28314621
Curator's Comment: description was created based on several sources, including
https://www.hsph.harvard.edu/nutritionsource/omega-3-fats/ |
https://www.ncbi.nlm.nih.gov/pubmed/24352849 |
https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm134064.htm
Doconexent (Docosahexaenoic acid, DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina. DHA is widely used as a food supplement, and is beleived to support healthy brain development in young childred, prevent cardiovascular disease and cognitive decline during Alzheimer's disease. Most of these claims, however, were not supported by clinical trials. DHA spray is used as a tanner.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1371883 |
|||
Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26359712 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of novel brain lipoxygenase products formed from docosahexaenoic acid (22:6w3). | 1988 |
|
Severe deficiency of docosahexaenoic acid in peroxisomal disorders: a defect of delta 4 desaturation? | 1990 Aug |
|
Hydrolysis of phosphatidylethanolamine by human pancreatic phospholipase A2. Effect of bile salts. | 1994 Feb |
|
Human plasma albumin transports [13C]docosahexaenoic acid in two lipid forms to blood cells. | 1997 Aug |
|
Differential distribution and metabolism of arachidonic acid and docosahexaenoic acid by human placental choriocarcinoma (BeWo) cells. | 1998 Aug |
|
Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule. | 1999 Apr |
|
Phytanic acid and docosahexaenoic acid increase the metabolism of all-trans-retinoic acid and CYP26 gene expression in intestinal cells. | 2001 Oct 31 |
|
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. | 2005 Jan |
|
TRPA1 is a polyunsaturated fatty acid sensor in mammals. | 2012 |
|
New therapy using omega-3-Acid ethyl esters for decubitus ulcers and stasis dermatitis: a case report. | 2014 Dec |
|
Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. | 2014 Jul |
|
Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia. | 2014 Nov |
|
Safety of docosahexaenoic acid (DHA) administered as DHA ethyl ester in a 9-month toxicity study in dogs. | 2016 Jun |
|
Kinetics of docosahexaenoic acid ethyl ester accumulation in dog plasma and brain. | 2016 Oct |
|
Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance. | 2017 Mar |
|
Uptake and tissue accretion of orally administered free carboxylic acid as compared to ethyl ester form of docosahexaenoic acid (DHA) in the rat. | 2018 |
|
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). | 2018 Aug 14 |
|
[Separation of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester by simulated moving bed chromatography]. | 2018 Sep 8 |
Patents
Sample Use Guides
Doconexent is administered with food or as an oral supplement, or topically with food.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1371883
DHA reduces calcium uptake in rat cardiac myocytes exposed to oubain (0.1 mM) after incubation for 4 days with 5 uM DHA added to medium. Calcium uptake was measured after addition of tracer 45Ca2+ to the 1.0 mM calcium in the bathing medium.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
319
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
NCI_THESAURUS |
C493
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
75095-0
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
90914-3
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
FDA ORPHAN DRUG |
432814
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
FDA ORPHAN DRUG |
141701
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
90908-5
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
88999-8
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
88998-0
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
35174-2
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
FDA ORPHAN DRUG |
456414
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
DSLD |
1010 (Number of products:2932)
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
NCI_THESAURUS |
C68345
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
FDA ORPHAN DRUG |
454314
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
FDA ORPHAN DRUG |
450214
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
90911-9
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
DSLD |
4096 (Number of products:5)
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
||
|
LOINC |
88995-6
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5040465
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
732
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
25167-62-8
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
1006469
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
ALTERNATIVE | |||
|
m4713
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
25377-50-8
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
SUPERSEDED | |||
|
ZAD9OKH9JC
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
ZAD9OKH9JC
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
36005
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
100000144929
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
2091-24-9
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
DB03756
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
DOCOSAHEXAENOIC ACID
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
28125
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
144450
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
6428
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
731
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
6217-54-5
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
SUB121918
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
73
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
ALTERNATIVE | |||
|
4289
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
445580
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL367149
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
C68346
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY | |||
|
1224609
Created by
admin on Fri Dec 15 15:32:21 GMT 2023 , Edited by admin on Fri Dec 15 15:32:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)